Circassia’s cat allergy treatment shows sustained symptom improvement
Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® cat allergy treatment.
The phase II study originally measured the level of patients’ symptoms following Toleromune® treatment, compared with placebo. Two years later, and having received no further ToleroMune® treatment, 50 of the original 202 patients were reassessed. The study showed that these patients maintained consistent symptom improvements both 12 and 24 months after the start of the treatment and found that the treatment reduced symptoms by two and a half to three times the level achieved by other allergy therapies in similar studies.
Circassia is currently conducting a phase III multinational study to test the safety and efficacy of the ToleroMune® treatment in approximately 1,200 subjects from the United States, Canada and Europe and results are expected in 2014.
The ToleroMune® allergy treatment is based on an approach of using synthetic peptides identified from allergens to induce immune tolerance in the body by generating regulatory T-cells which suppress allergic responses.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
